Conversely, the AhR agonist, 6-formylindolo[3,2-b]carbazole (FICZ), increased the proportion of TRAIL+ LrNK cells by upregulating FoxO1 expression, thereby enhancing local anti-tumor immune activity [67] (Fig. 2h). Here, TNFSF10 is linked to neoplasm.